About ICE Bioscience
ICE Bioscience is a company based in Beijing (China) founded in 2010. ICE Bioscience has raised $14.03 million across 2 funding rounds from investors including E-Town International Investment & Development, Alwin Capital and Yida Capital. ICE Bioscience operates in a competitive market with competitors including Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others.
- Headquarter Beijing, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.03 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ICE Bioscience
ICE Bioscience has successfully raised a total of $14.03M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ICE Bioscience
ICE Bioscience has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include E-Town International Investment & Development, Alwin Capital and Yida Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed on a global scale.
|
Locked | Locked | Locked | |
|
Alwin Capital is focused on life sciences investment opportunities.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for ICE Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ICE Bioscience
Investment portfolio details for ICE Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ICE Bioscience
Detailed financials for ICE Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ice Bioscience Comparisons
Peer comparison for ICE Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ICE Bioscience
ICE Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and BCI Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| Locked | Locked | Locked |
High-dimensional immune profiling services are delivered via proprietary platform.
|
|
| Locked | Locked | Locked |
A CRO that provides phenotypic assay development and screening services.
|
|
| Locked | Locked | Locked |
Custom human cell engineering and drug discovery services are provided.
|
|
| Locked | Locked | Locked |
Contract research services in cancer and neuroinflammation are offered.
|
Detailed competitors of ICE Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ice Bioscience
Complete news archive for ICE Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ICE Bioscience
ICE Bioscience was founded in 2010 and raised its 1st funding round 12 years after it was founded.
ICE Bioscience is headquartered in Beijing, China.
ICE Bioscience is a funded company, having raised a total of $14.03M across 2 funding rounds to date.
ICE Bioscience was founded in 2010 and is based in Beijing, China. As a preclinical contract research organization, expertise in electrophysiology is utilized to deliver ion channel-based screening services. Cardiac safety assessments, such as hERG testing and QT-prolongation evaluation, are conducted. Profiling of voltage-gated, ligand-gated, CRAC, and chloride channels is offered. In-vitro high-throughput screening, including GPCR and protein kinase assays along with cell line development, is also provided.
ICE Bioscience's top competitors include ImmunoSCAPE, Quantumcyte and Reaction Biology.
ICE Bioscience has 9 investors. Key investors include E-Town International Investment & Development, Alwin Capital, Yida Capital, Jifeng Ventures, and CICC Capital.